Clinical Pathway for the Diagnosis and Management of Patients With Relapsing-Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population

被引:0
|
作者
Caparo-Zamalloa, Cesar [1 ,2 ,3 ]
Velasquez-Rimachi, Victor [3 ,4 ,5 ]
Mori, Nicanor [3 ,6 ]
Duenas-Pacheco, Wenzel Ivan [7 ]
Huerta-Rosario, Andrely [4 ,5 ,8 ]
Farronay-Garcia, Chandel [4 ,9 ]
Molina, Roberto A. [4 ,5 ,7 ]
Alva-Diaz, Carlos [5 ]
机构
[1] Inst Nacl Ciencias Neurol, Basic Res Ctr Dementias & Cent Nervous Syst Demye, Lima, Peru
[2] Clin Delgado, Neurosonol, Lima, Peru
[3] Univ Nacl Mayor San Marcos, Fac Med, Lima, Peru
[4] Red Eficacia Clin & Sanitaria REDECS, Lima, Peru
[5] Univ Cient Sur, Grp Invest Neurociencia Efectividad Clin & Salud, Lima, Peru
[6] Hosp Daniel Alcides Carrion, Dept Med & Oficina Apoyo Docencia & Invest OADI, Serv Neurol, Callao, Peru
[7] Hosp Nacl Maria Auxiliadora, Serv Neurol, Lima, Peru
[8] Univ Nacl Federico Villarreal, Fac Med Hipolito Unanue, Lima, Peru
[9] Inst Nacl Salud INS, Lima, Peru
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
关键词
multiple sclerosis; relapsing-remitting; patient care management; critical pathways; Peru; INTRAVENOUS METHYLPREDNISOLONE; ORAL CLADRIBINE; CARE; OCRELIZUMAB; CONVERSION; TRIAL; GUIDELINE; RITUXIMAB; SAFETY; TIME;
D O I
10.3389/fneur.2021.667398
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Relapsing-remitting multiple sclerosis (RRMS) is a subtype of degenerative inflammatory demyelinating disease of multifactorial origin that affects the central nervous system and leads to multifocal neurological impairment.</p> Objectives: To develop a clinical pathway (CP) for the management of Peruvian patients with RRMS.</p> Methods: First, we performed a literature review using Medline, Embase, Cochrane, ProQuest, and Science direct. Then, we structured the information as an ordered and logical series of five topics in a defined timeline: (1) How should MS be diagnosed? (2) How should a relapse be treated? (3) How should a DMT be initiated? (4) How should each DMT be used? and (5) How should the patients be followed?</p> Results: The personnel involved in the care of patients with RRMS can use a series of flowcharts and diagrams that summarize the topics in paper or electronic format.</p> Conclusions: We propose the first CP for RRMS in Peru that shows the essential steps for diagnosing, treating, and monitoring RRMS patients based on an evidence-based medicine method and local expert opinions. This CP will allow directing relevant clinical actions to strengthen the multidisciplinary management of RRMS in Peru.</p>
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Current management of relapsing-remitting multiple sclerosis
    Sedal, L.
    Wilson, I. B.
    McDonald, E. A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 950 - 957
  • [2] The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis
    Datt, Joe
    Baldock, Laura
    Pull, Emily
    Webber, Bryn
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 5 : 40 - 46
  • [3] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [4] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Mansour A. Alharbi
    Fahad Aldosari
    Ahmed Hasan Althobaiti
    Faris M. Abdullah
    Salman Aljarallah
    Nuha M. Alkhawajah
    Miteb Alanazi
    Yazed AlRuthia
    BMC Health Services Research, 23
  • [5] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Alharbi, Mansour A.
    Aldosari, Fahad
    Althobaiti, Ahmed Hasan
    Abdullah, Faris M.
    Aljarallah, Salman
    Alkhawajah, Nuha M.
    Alanazi, Miteb
    AlRuthia, Yazed
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [6] Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis
    Nocentini, U
    Pasqualetti, P
    Bonavita, S
    Buccafusca, M
    De Caro, MF
    Farina, D
    Girlanda, P
    Le Pira, F
    Lugaresi, A
    Quattrone, A
    Reggio, A
    Salemi, G
    Savettieri, G
    Tedeschi, G
    Trojano, M
    Valentino, P
    Caltagirone, C
    MULTIPLE SCLEROSIS, 2006, 12 (01): : 77 - 87
  • [7] Neurovascular coupling in patients with relapsing-remitting multiple sclerosis
    Uzuner, Gulnur Tekgol
    Uzuner, Nevzat
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 146 : 24 - 28
  • [8] Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management
    Bittner, Stefan
    Ruck, Tobias
    Wiendl, Heinz
    Grauer, Oliver M.
    Meuth, Sven G.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (01) : 51 - 66
  • [9] The Effect of Rituximab on the Cognitive Function of Patients with Relapsing-Remitting Multiple Sclerosis
    Najafi, Masood
    Farahmand, Ghasem
    Balali, Pargol
    Behkar, Atefeh
    Shahbazi, Mojtaba
    Moradian, Negar
    Pouyanmanouchehri, Sara
    Harirchian, Mohammad Hossein
    Ranji, Sara
    CLINICAL THERAPEUTICS, 2024, 46 (10) : e1 - e5
  • [10] Significance of the Diagnosis of Executive Functions in Patients with Relapsing-Remitting Multiple Sclerosis
    Borkowska, Aneta R.
    Daniluk, Beata
    Adamczyk, Katarzyna
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (19)